Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cassava Sciences Inc (FLNA) vs Somnigroup International Inc. Common Stock (SGI) Price & Performance

Cassava Sciences IncTrade
Somnigroup International Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

Cassava Sciences Inc vs Somnigroup International Inc. Common Stock — how do they compare? Cassava Sciences Inc trades at $0.71 (market cap $35.91M), while Somnigroup International Inc. Common Stock trades at $62 (market cap $14.48B). The key difference: Somnigroup International Inc. Common Stock is far larger — about 403.2× Cassava Sciences Inc's market cap, and Somnigroup International Inc. Common Stock pays a 1.08% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 38 Days and Somnigroup International Inc. Common Stock for 0 Days on average.

FLNASGI
Market Cap
$35.91M$14.48B
Volume
323,2461,734,399
Sector
HealthConsumer Cyclical
52-Week High
$4.64$97.99
52-Week Low
$0.68$61.49
Typical Hold Time
38 Days0 Days
Enterprise Value
-$46.77M$20.78B
Dividend Yield
—1.08%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cassava Sciences Inc

FLNA trades at $0.7316, down 4.93% today, amid bearish technical signals despite recent FDA progress. The stock shows negative profitability with ROE at -55.79% and consistent negative cash flow, though it has beaten EPS estimates for three consecutive quarters. Analyst consensus remains positive with 8 buy ratings versus 4 holds.

The outlook hinges on clinical development success, particularly the Phase 2a study for TSC-related epilepsy. Investment opportunity exists if trials progress favorably, but risks include cash burn, regulatory hurdles, and persistent losses. Current valuation metrics like EV/EBITDA of 1.11 suggest potential upside if execution improves.

Somnigroup International Inc. Common Stock

Somnigroup International (SGI) trades at $62.87, up 0.75% with neutral technical signals. The company shows strong profitability with 44.24% gross margins and has beaten earnings estimates for three consecutive quarters. Recent acquisition of Leggett & Platt enhances vertical integration with $75M synergy target. Analyst consensus is strongly bullish with 91% buy ratings and $94.50 price target, representing 50% upside potential from current levels.

SGI presents compelling growth prospects through strategic acquisitions and operational efficiencies, though faces margin pressures in weak bedding markets. The stock trades at reasonable valuations (P/E 24.85) with improving cash flow trends expected in 2026. Key risks include integration execution and market competition, but strong institutional interest and insider buying support the bullish case.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

FLNA
52% Buy48% Sell
Avg holding period · 38 Days
SGI
100% Buy0% Sell
Avg holding period · 0 Days

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA →

About Somnigroup International Inc. Common Stock

Somnigroup International Inc. (formerly Tempur Sealy International) is a bedding and sleep-products company that designs, manufactures, distributes, and retails mattresses and related products. It operates through Tempur Sealy North America, Tempur Sealy International, and Mattress Firm, with brands including Tempur-Pedic, Sealy, Stearns & Foster, and Mattress Firm.

Read more on SGI →